These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22563628)

  • 1. Safety and tolerability of antipsychotic polypharmacy.
    Gallego JA; Nielsen J; De Hert M; Kane JM; Correll CU
    Expert Opin Drug Saf; 2012 Jul; 11(4):527-42. PubMed ID: 22563628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using an Integrated Care Pathway for Late-Life Schizophrenia Improves Monitoring of Adverse Effects of Antipsychotics and Reduces Antipsychotic Polypharmacy.
    Abdool PS; Supasitthumrong T; Patel K; Mulsant BH; Rajji TK
    Am J Geriatr Psychiatry; 2019 Jan; 27(1):84-90. PubMed ID: 30396766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.
    Ijaz S; Bolea B; Davies S; Savović J; Richards A; Sullivan S; Moran P
    BMC Psychiatry; 2018 Sep; 18(1):275. PubMed ID: 30176844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale.
    Azorin JM; Simon N
    Expert Opin Drug Metab Toxicol; 2020 Dec; 16(12):1175-1186. PubMed ID: 32930009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings.
    Rani FA; Byrne PJ; Murray ML; Carter P; Wong IC
    Drug Saf; 2009; 32(4):325-33. PubMed ID: 19388723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].
    Haefliger T; Bonsack C
    Encephale; 2006; 32(1 Pt 1):97-105. PubMed ID: 16633296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic polypharmacy and adverse drug reactions among adults in a London mental health service, 2008-2018.
    Yang JC; Thygesen JH; Werbeloff N; Hayes JF; Osborn DPJ
    Psychol Med; 2023 Jul; 53(9):4220-4227. PubMed ID: 35485715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.
    Henderson DC; Doraiswamy PM
    J Clin Psychiatry; 2008; 69 Suppl 1():32-44. PubMed ID: 18484806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
    Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic polypharmacy or monotherapy?
    Gardos G
    Neuropsychopharmacol Hung; 2005 Jun; 7(2):72-7. PubMed ID: 16167458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy, safety, and tolerability of antipsychotics in the elderly.
    Maixner SM; Mellow AM; Tandon R
    J Clin Psychiatry; 1999; 60 Suppl 8():29-41. PubMed ID: 10335669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
    Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
    Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies.
    Meduri M; Gregoraci G; Baglivo V; Balestrieri M; Isola M; Brambilla P
    J Affect Disord; 2016 Feb; 191():187-208. PubMed ID: 26674213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.
    Lochmann van Bennekom MW; Gijsman HJ; Zitman FG
    J Psychopharmacol; 2013 Apr; 27(4):327-36. PubMed ID: 23413275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of atypical antipsychotics : differential risk and clinical implications.
    Haddad PM; Sharma SG
    CNS Drugs; 2007; 21(11):911-36. PubMed ID: 17927296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
    Ayenew W; Asmamaw G; Bitew T
    Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexual dysfunction in people treated with long-acting injectable antipsychotics in monotherapy or polypharmacy: a naturalistic study.
    Martínez-Giner G; Giménez-De Llano E; Romero-Rubio D; Abad-Pérez MJ; Sánchez-Martínez V
    Int J Ment Health Nurs; 2022 Jun; 31(3):576-590. PubMed ID: 34973049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some adverse effects of antipsychotics: prevention and treatment.
    Lader M
    J Clin Psychiatry; 1999; 60 Suppl 12():18-21. PubMed ID: 10372605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.